Stanford scientists have discovered that certain immune receptors become more active in hematopoietic stem cells with age. This change leads to increased production of myeloid cells in the bone marrow.
Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.
There are two subsets of Hematopoietic stem cells (HSC); one subset that provides balanced production of myeloid and lymphoid cells, and another that is biased toward production of the myeloid lineage.
Obtaining pure cell types from mixed cell populations continues to be a significant obstacle in the fields of stem cell biology and regenerative medicine.
Stanford researchers in the Weissman lab have developed an engineered protein that blocks the function of the CD47 mimics pathogens use to evade the immune system.
Researchers at Stanford have developed a method of using intact genetically modified pathogens for more sensitive and accurate diagnosis of pathogenic infection.
Researchers at Stanford have developed agents to enhance the therapeutic efficacy of a variety of anti-cancer therapeutics. Cell loss by apoptosis occurs in normal development and in tumor environments.
Researchers in Prof. Irving Weissman's laboratory have developed cell culture techniques to rapidly and efficiently derive pure populations of mesodermal cells from human pluripotent stem cells (hPSCs).
Researchers at Stanford have developed methods to enhance bone healing in diabetic patients, who often suffer from impaired fracture healing due to a deficiency in hedgehog signaling in their skeletal stem cells.
Researchers in Prof. Irving Weissman's lab have developed and patented antibodies and methods to prevent the formation of teratomas from human pluripotent stem cells used for regenerative medicine, cell therapy or research.